20/20 Biolabs Stock Price, News & Analysis
Company Description
20/20 Biolabs (NASDAQ: AIDX) is a publicly traded medical devices company in the Healthcare sector. The company has a market capitalization of $18.0M, ranking #6,219 among all listed U.S. companies by market cap.
AIDX stock has declined 92.5% over the past year. Shares last traded at $1.76.
On a trailing twelve-month basis, 20/20 Biolabs reported revenue of $2.0M with net income of -$3.7M and diluted earnings per share of $-0.76. The company operates at a net profit margin of -182.8%.
This page provides a comprehensive overview of AIDX stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
20/20 Biolabs (AIDX) stock last traded at $1.76, up 3.14% from the previous close. Over the past 12 months, the stock has lost 92.5%. At a market capitalization of $18.0M, AIDX is classified as a micro-cap stock with approximately 10.4M shares outstanding.
Latest News
20/20 Biolabs has 6 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 4 with negative movement. Key topics include earnings, AI. View all AIDX news →
SEC Filings
20/20 Biolabs has filed 5 recent SEC filings, including 2 Form 424B3, 2 Form EFFECT, 1 Form 4. The most recent filing was submitted on April 13, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all AIDX SEC filings →
Financial Highlights
20/20 Biolabs generated $2.0M in revenue over the trailing twelve months, retaining a 29.6% gross margin, operating income reached -$3.3M (-162.9% operating margin), and net income was -$3.7M, reflecting a -182.8% net profit margin. Diluted earnings per share stood at $-0.76. The company generated -$1.9M in operating cash flow. With a current ratio of 0.60, short-term liquidity bears monitoring.
Upcoming Events
Medicare coverage begins
20/20 Biolabs has 1 upcoming scheduled event. The next event, "Medicare coverage begins", is scheduled for January 1, 2028 (in 622 days). Investors can track these dates to stay informed about potential catalysts that may affect the AIDX stock price.
Short Interest History
Short interest in 20/20 Biolabs (AIDX) currently stands at 54.2 thousand shares, up 188.0% from the previous reporting period, representing 0.5% of the float. Over the past 12 months, short interest has increased by 188%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for 20/20 Biolabs (AIDX) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
AIDX Company Profile & Sector Positioning
20/20 Biolabs (AIDX) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.